



Copy of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from IDWeek 2023 and the authors of the poster.



SHIONOGI

OBJECTIVES

We aimed to describe cefiderocol usage in the treatment of patients with Gram-negative bacterial infections, without COVID-19, and for whom microbiology data were available from US hospitals between January 2020 and June 2022.

METHODS

**Design:** retrospective multicenter observational study.

**Data source:** PINC AI database from January 2020 to June 2022.


**Inclusion criteria:** adult non-COVID hospitalized patients treated with cefiderocol consecutively for ≥3 days after laboratory confirmed Gram-negative bacterial infections.

**Endpoints:** patient characteristics, microbiological profile, and overall, Day 14 and Day 28, in-hospital all-cause mortality (IHACM).

**Index culture** was defined as the first clinical culture with a Gram-negative pathogen during hospitalization. All pathogens identified from the index culture were index isolates.




RESULTS

Patient attrition



COVID-19, coronavirus disease 2019.

RESULTS



Treatment and hospitalization outcomes	Overall (N=275)
Days on cefiderocol, median (Q1–Q3)	9 (6–15)
Days from index culture to starting cefiderocol, median (Q1–Q3)	6 (3–11)
Cefiderocol used as monotherapy, n (%)	92 (33.5)
Received other Gram-negative antibiotics before cefiderocol, n (%)	253 (92.0)

In-hospital mortality	n/N, (% [95% CI])
All-cause mortality	45/275 (16.4% [12.0%–20.7%])
Initiating cefiderocol ≤5 days of index culture (n=135)	14/135 (10.4% [5.2%–15.5%])
6–20 days of index culture (n=108)	21/108 (19.4% [12%–26.9%])
>20 days of index culture (n=32)	10/32 (31.3% [8.2%–15.2%])
Death within 14 days from initiating cefiderocol	23/275 (8.4% [5.1%–11.6%])
Death within 28 days from initiating cefiderocol	35/275 (12.7% [8.8%–16.7%])
Death within 14 days from index culture	10/275 (3.6% [1.4%–5.9%])
Death within 28 days from index culture	26/275 (9.5% [6.0%–12.9%])

CONCLUSIONS

The study demonstrated that cefiderocol is effective in treating US patients with Gram-negative infections. Patients receiving cefiderocol earlier had lower IHACM than those receiving cefiderocol later, but further investigations are needed to confirm this finding.